© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
January 30, 2023
Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.
January 28, 2023
The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.
January 26, 2023
The DGX-A01 study met its primary safety and efficacy endpoints in its highest dose cohort of IDCT.
Breyanzi is currently approved for the second-line or later treatment of large B-cell lymphomas.
January 25, 2023
Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.
The CD19/CD20 dual-targeted CAR is currently under investigation in an investigator-initiated study in UCLA.
January 24, 2023
The FAD has granted primary IND clearance to the company’s T-Plex program and 2 initial TCR-T therapies.
NGN-401 is Neurogene’s second investigational gene therapy to enter clinical trials.
With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.
January 20, 2023
The FDA has lifted a clinical hold placed in the summer of 2022 due to a mild but medically significant case of peripheral sensory neuropathy.